118 related articles for article (PubMed ID: 18547964)
21. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
[TBL] [Abstract][Full Text] [Related]
22. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
[TBL] [Abstract][Full Text] [Related]
23. Expression of PLK1 and survivin in diffuse large B-cell lymphoma.
Liu L; Zhang M; Zou P
Leuk Lymphoma; 2007 Nov; 48(11):2179-83. PubMed ID: 17943598
[TBL] [Abstract][Full Text] [Related]
24. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
Liu L; Zhang M; Zou P; Tian L; Liu F
Ai Zheng; 2006 Apr; 25(4):404-8. PubMed ID: 16613670
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.
Weichert W; Schmidt M; Jacob J; Gekeler V; Langrehr J; Neuhaus P; Bahra M; Denkert C; Dietel M; Kristiansen G
Pancreatology; 2005; 5(2-3):259-65. PubMed ID: 15855824
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
27. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
28. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
29. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Weichert W; Schmidt M; Gekeler V; Denkert C; Stephan C; Jung K; Loening S; Dietel M; Kristiansen G
Prostate; 2004 Aug; 60(3):240-5. PubMed ID: 15176053
[TBL] [Abstract][Full Text] [Related]
30. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
Duan Z; Ji D; Weinstein EJ; Liu X; Susa M; Choy E; Yang C; Mankin H; Hornicek FJ
Cancer Lett; 2010 Jul; 293(2):220-9. PubMed ID: 20144850
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
34. PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome.
Sandison HE; Usher S; Karimiani EG; Ashton G; Menasce LP; Radford JA; Linton K; Byers RJ
J Clin Pathol; 2013 Sep; 66(9):764-7. PubMed ID: 23757039
[TBL] [Abstract][Full Text] [Related]
35. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.
Lei M; Erikson RL
Oncogene; 2008 Jun; 27(28):3935-43. PubMed ID: 18297112
[TBL] [Abstract][Full Text] [Related]
36. Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid.
Ito Y; Yoshida H; Matsuzuka F; Matsuura N; Nakamura Y; Nakamine H; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2004; 24(1):259-63. PubMed ID: 15015605
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
Singh L; Pushker N; Sen S; Singh MK; Chauhan FA; Kashyap S
Clin Exp Ophthalmol; 2015 Aug; 43(6):550-7. PubMed ID: 25754767
[TBL] [Abstract][Full Text] [Related]
38. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.
Oliveira JC; Pezuk JA; Brassesco MS; Morales AG; Queiroz RG; Scrideli CA; Tone LG
Pediatr Blood Cancer; 2014 Jul; 61(7):1227-31. PubMed ID: 24519995
[TBL] [Abstract][Full Text] [Related]
39. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
Weichert W; Denkert C; Schmidt M; Gekeler V; Wolf G; Köbel M; Dietel M; Hauptmann S
Br J Cancer; 2004 Feb; 90(4):815-21. PubMed ID: 14970859
[TBL] [Abstract][Full Text] [Related]
40. Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas.
Mito K; Kashima K; Kikuchi H; Daa T; Nakayama I; Yokoyama S
Leuk Lymphoma; 2005 Feb; 46(2):225-31. PubMed ID: 15621805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
